[{"id":"39a90bf8-9568-4364-b367-7f7a5182fa7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04163575","created_at":"2021-01-18T20:18:14.363Z","updated_at":"2024-07-02T16:36:52.134Z","phase":"Phase 1/2","brief_title":"Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL","source_id_and_acronym":"NCT04163575","lead_sponsor":"Kecellitics Biotech Company Ltd","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD22-CAR"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 02/01/2020","start_date":" 02/01/2020","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2019-12-23"}]